Shell Asset Management’s Legend Biotech LEGN Stock Holding History

Shell Asset Management’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$169K	Buy	5,171 +3,056	+144%	+$113K	0.02%	519
2025 Q2	$75K	Buy	2,115 +25	+1%	+$810	﹤0.01%	1063
2025 Q1	$71K	Hold	2,090	–	–	﹤0.01%	1082
2024 Q4	$68K	Buy	2,090 +800	+62%	+$33.1K	﹤0.01%	1128
2024 Q3	$63K	Buy	+1,290	New	+$68.7K	﹤0.01%	1147
2024 Q1	$79K	Buy	1,790 +590	+49%	+$35.6K	﹤0.01%	1078
2023 Q4	$72K	Hold	1,200	–	–	﹤0.01%	1125
2023 Q3	$81K	Hold	1,200	–	–	﹤0.01%	1125
2023 Q2	$83K	Sell	1,200 -3,900	-76%	-$255K	﹤0.01%	1153
2023 Q1	$246K	Hold	5,100	–	–	0.01%	860
2022 Q4	$255K	Buy	5,100 +2,100	+70%	+$102K	0.01%	851
2022 Q3	$122K	Sell	3,000 -4,600	-61%	-$216K	﹤0.01%	1157
2022 Q2	$418K	Buy	+7,600	New	+$321K	0.01%	810

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Shell Asset Management's LEGN Position: Q3 2025 in Review

Shell Asset Management increased its Legend Biotech (LEGN) stake by 144% in Q3 2025, buying an estimated $113K and bringing the position to 5,171 shares worth $169K. The position accounts for 0.02% of the portfolio, ranked #519.

Shell Asset Management first reported a position in LEGN in Q2 2022 and has held it in 13 quarters since. The position peaked at $418K in Q2 2022. 200 funds tracked by Wall St. Rank hold LEGN as of Q3 2025.

Shell Asset Management held 5,171 shares of Legend Biotech worth $169K as of Q3 2025.
Shell Asset Management bought 3,056 Legend Biotech shares in Q3 2025, an estimated $113K.
Legend Biotech made up 0.02% of Shell Asset Management's portfolio in Q3 2025, its #519 holding.
Shell Asset Management first reported a position in Legend Biotech in Q2 2022 and has held it in 13 quarters since.
Shell Asset Management's Legend Biotech position peaked at $418K in Q2 2022.
200 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.